Onivyde sales and marketing update

The U.K.’s NICE issued draft guidance recommending against the use of Onivyde irinotecan from Shire in combination with 5-fluorouracil (5-FU) and leucovorin to treat metastatic pancreatic cancer in patients who progressed following gemcitabine-based therapy. The agency said the most plausible incremental cost-effectiveness ratio (ICER) for the combination therapy was over £100,000 ($124,740) per quality-adjusted life year (QALY) gained and that the therapy did not qualify for end-of-life consideration...